Illumina’s Grail quest results in epic fine

By Anthony King2023-07-26T13:36:00

A woman speaking at an European Commission lecture. Behind her is a large projected slide which says EU Merger Control: Illumina / GRAIL

Source: © Thierry Monasse/Getty Images

EU and US competition authorities object to firms completing merger without approval

The EU slapped gene sequencing company Illumina with a record €432 million (£372 million) fine in July for going ahead with its acquisition of cancer detection firm Grail before competition authorities had cleared the deal.